Clinical Trials Logo

Malignant Paraganglioma clinical trials

View clinical trials related to Malignant Paraganglioma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04860700 Recruiting - Clinical trials for Malignant Paraganglioma

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Start date: April 30, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well anlotinib hydrochloride works in treating patients with metastatic pheochromocytoma or paraganglioma. Anlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.